The Global Controlled Release Drug Delivery Market size is expected to reach $106.3 billion by 2030, rising at a market growth of 10.4% CAGR during the forecast period.
The coacervation provides various benefits including improved effectiveness, fewer side effects, convenience, and guaranteed linear medication administration over a predetermined duration, therefore, coacervation segment acquired $5,289.0 million revenue in the market in 2022. Coacervates are a novel family of drug delivery agents created to transport proteins and small-molecule medications. Among these are coacervates made of heparin that hold artificial polycations for the regulated delivery of growth factors. With more people using these devices, they are expected to soon increase in demand for controlled release drug delivery. Some of the factors impacting the market are growing application of non-invasive drug delivery techniques, increase in global aging population proportion, and Challenges in controlled release drug formulation preparation.
Because of technological improvements in medicine and straightforward oral drug delivery methods, the non-invasive mode of targeted medication delivery is now capable of competing with traditional injectables as well as uncomfortable routes of drug delivery. These drug delivery systems are rapidly displacing some of the most common injections given to patients with certain diseases. For example, hypodermic injections are painful, create hazardous medical waste, and raise the risk of disease transmission through reused needles, especially in developing countries. The elderly population is increasing quickly in every nation on the earth. Nearly 1.5 billion people will inhabit this world by 2050, an increase of more than three times the current number. Additionally, during this time, it is predicted that the percentage of elderly citizens will increase to 16.0% worldwide. In the middle of the twenty-first century, one in six people will be 65 or older. The "population aging phenomenon" describes the rise in the proportion and prevalence of older persons globally. Additionally, 703 million people worldwide were 65 or older in 2019. In 2019, there were 9% more persons aged 65 and over than there were in 2018. With the world's aging population growing and these individuals being more susceptible to age-related problems, it is projected that increased demand for novel drug delivery systemswill fuel market expansion.
Due to the rising need for solutions for controlled release drug administration, the COVID-19 pandemic had a favorable effect on the market's growth. For instance, the September 2021 publication of an article titled "Role of Novel Drug Delivery Systems in Coronavirus Disease-2019 (COVID-19): Time to Act Now" demonstratedthe impending increase in the use and demand for novel drug delivery systems and technologies. This facilitated therelease ofseveral novel drug delivery systems anddevices, which helped repurpose the existing medications to treat various viral illnesses.
However, drug-related formulation challenges include active pharmaceutical ingredients with short half-lives and the need for higher dose delivery, as well as formulation-related issues. This frequently calls for soluble handling capabilities because most polymers need to be dissolved in natural solvents before being covered by controlled-release formulations (such as tablets, granules, and capsules). Additionally, dumping of doses is a key drawback of controlled release formulation. Dose modification is more challenging in formulations with controlled release. Therefore, themarket expansion may be slowed by any technological setbacks or delays.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Merck & Co., Inc., Alkermes PLC, Pfizer, Inc., Assertio Holdings, Inc. (Assertio Therapeutics, Inc.), Lonza Group AG (Capsugel), Colorcon, Inc. (BPSI Holdings LLC.), Corium, LLC (Gurnet Point Capital), Adare Pharma Solutions, and Coating Place, Inc.
The coacervation provides various benefits including improved effectiveness, fewer side effects, convenience, and guaranteed linear medication administration over a predetermined duration, therefore, coacervation segment acquired $5,289.0 million revenue in the market in 2022. Coacervates are a novel family of drug delivery agents created to transport proteins and small-molecule medications. Among these are coacervates made of heparin that hold artificial polycations for the regulated delivery of growth factors. With more people using these devices, they are expected to soon increase in demand for controlled release drug delivery. Some of the factors impacting the market are growing application of non-invasive drug delivery techniques, increase in global aging population proportion, and Challenges in controlled release drug formulation preparation.
Because of technological improvements in medicine and straightforward oral drug delivery methods, the non-invasive mode of targeted medication delivery is now capable of competing with traditional injectables as well as uncomfortable routes of drug delivery. These drug delivery systems are rapidly displacing some of the most common injections given to patients with certain diseases. For example, hypodermic injections are painful, create hazardous medical waste, and raise the risk of disease transmission through reused needles, especially in developing countries. The elderly population is increasing quickly in every nation on the earth. Nearly 1.5 billion people will inhabit this world by 2050, an increase of more than three times the current number. Additionally, during this time, it is predicted that the percentage of elderly citizens will increase to 16.0% worldwide. In the middle of the twenty-first century, one in six people will be 65 or older. The "population aging phenomenon" describes the rise in the proportion and prevalence of older persons globally. Additionally, 703 million people worldwide were 65 or older in 2019. In 2019, there were 9% more persons aged 65 and over than there were in 2018. With the world's aging population growing and these individuals being more susceptible to age-related problems, it is projected that increased demand for novel drug delivery systemswill fuel market expansion.
Due to the rising need for solutions for controlled release drug administration, the COVID-19 pandemic had a favorable effect on the market's growth. For instance, the September 2021 publication of an article titled "Role of Novel Drug Delivery Systems in Coronavirus Disease-2019 (COVID-19): Time to Act Now" demonstratedthe impending increase in the use and demand for novel drug delivery systems and technologies. This facilitated therelease ofseveral novel drug delivery systems anddevices, which helped repurpose the existing medications to treat various viral illnesses.
However, drug-related formulation challenges include active pharmaceutical ingredients with short half-lives and the need for higher dose delivery, as well as formulation-related issues. This frequently calls for soluble handling capabilities because most polymers need to be dissolved in natural solvents before being covered by controlled-release formulations (such as tablets, granules, and capsules). Additionally, dumping of doses is a key drawback of controlled release formulation. Dose modification is more challenging in formulations with controlled release. Therefore, themarket expansion may be slowed by any technological setbacks or delays.
Application Outlook
On the basis of application, the controlled release drug delivery market is classified into metered dose inhalers, injectable, transdermal & ocular patches, infusion pumps & drug eluting stents, and oral controlled drug delivery systems. The oral controlled drug delivery systems segment procured the largest revenue share in the controlled release drug delivery market in 2022. By getting beyond obstacles such as low solubility, enzymatic degradation, and first-pass metabolism, oral controlled drug delivery systems can increase the bioavailability of pharmaceuticals. They can speed up the absorption of the medicine and prevent it from degrading in the GI tract, leading to higher and more reliable drug concentrations in the bloodstream. As the drug stays at the target location for a longer period and provides sustained pharmacological activity, this increased drug delivery can improve therapeutic effectiveness.
Technology Outlook
Based on technology, the controlled release drug delivery market is characterized into Wurster technique, coacervation, micro encapsulation, implants, transdermal, targeted delivery, and others. The micro encapsulation segment procured a considerable growth rate in the controlled release drug delivery market in 2022. Over the projected period, the demand for controlled medication release of extremely complex and unstable compounds, including proteins, antioxidants, and vitamins,is expected to increase. Thisis projected to support the expansion of the micro encapsulation segment. For example, vitamin A has weak chemical stability and water solubility; nevertheless, when it is micro encapsulated, the shelf life of the product rises, aiding in the achievement of controlled drug release concurrently.Release Mechanism Outlook
On the basis of release mechanism, the controlled release drug delivery market is classified into polymer-based systems, micro reservoir partition controlled drug delivery systems, feedback regulated drug delivery systems, activation-modulated drug delivery systems, and chemically activated. The feedback regulated drug delivery systems segment recorded the largest revenue share in the controlled release drug delivery market in 2022. Due to its therapeutic effectiveness in treating conditions like diabetes, feedback-regulated medication delivery devices are becoming more popular. Furthermore, it is anticipated that rising R&D efforts to develop feedback-regulated, controlled drug delivery systems as antidotes will support market expansion.Regional Outlook
Region wise, the controlled release drug delivery market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment witnessed the maximum revenue share in the controlled release drug delivery market in 2022. It is projected that increased investment in research and development, in addition to government initiatives that have been carried out to encourage the development of controlled release systems, will drive market expansion in this region. The presence of large market participants is another factor that contributes to the encouragement of the development of controlled release systems. The rise of the demand for these products is helped along by the rising prevalence of chronic ailments such as cancer, diabetes, and heart diseases.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Merck & Co., Inc., Alkermes PLC, Pfizer, Inc., Assertio Holdings, Inc. (Assertio Therapeutics, Inc.), Lonza Group AG (Capsugel), Colorcon, Inc. (BPSI Holdings LLC.), Corium, LLC (Gurnet Point Capital), Adare Pharma Solutions, and Coating Place, Inc.
Strategies Deployed in the Market
- Jun-2023: Colorcon Inc. introduced HyperStart C2C, the Smart Formulation Hub to offer its customers formulation design for solid oral dosage forms. The launched digital platform for solid dosage from design and development decreases time and effort from core to coating.
- Apr-2023: Assertio Holdings, Inc. took over Spectrum Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company. The acquisition of Spectrum’s commercial abilities and ROLVEDON, a novel long-acting G-CSF product. Furthermore, ROLVEDON's release for the benefit of patients maximizes its potential and propels further growth.
- Nov-2022: Lonza released Capsugel Enprotect, a new capsule to deliver acid-sensitive APIs to the intestine. The launched capsule doesn't break during stomach transit and only releases its content in the intestine. Furthermore, Lonza would be able to address transforming demands while meeting regulatory requirements for various nutraceutical and pharmaceutical applications.
- Sep-2022: Corium announced the launch of Adlarity, a donepezil transdermal system for prescription usage across the United States. The Adlarity offers continuous doses of donepezil through the skin that treats patients with mild, medium, or critical dementia of Alzheimer's type.
- Aug-2022: Merck & Co., Inc. announced expanded production of its facility based in Carlow. The expansion would play a key role in making sure that they continue to sustain future supply to meet medical requirements.
- Mar-2022: Johnson & Johnson’s Janssen Pharmaceuticals came into an extended collaboration with Midatech Pharma, a drug delivery technology company. The collaboration focuses on enhancing drug loading and optimizing in vitro time of release for the undisclosed Janssen experimental molecule combined with Midatech’s Q-Sphera technology.
- Dec-2021: Pfizer expanded its geographical footprint by opening a new clinical manufacturing facility in Durham, North Carolina. The new facility broadens Pfizer's complete range of capabilities in gene therapy and builds on the company's existing presence.
- Dec-2021: Adare Pharma Solutions acquired Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. This acquisition strengthens Adare's aim to transform drug delivery by offering leading solutions from product development through commercial-scale packaging and manufacturing.
- Oct-2021: Colorcon completed the acquisition of Ideal Cures, a manufacturer of excipients and ready-to-use coating systems for solid oral dosage. This acquisition of Ideal Cures aimed at underscoring the importance of India in the pharmaceutical sector by providing an expanded service network of manufacturing & technical capabilities, especially for the remotely located economic zones.
- May-2021: Colorcon expanded its geographical footprints in Harleysville, PA, USA by opening a new Containment Suite located. This expansion would provide the Colorcon capabilities to develop prototype tablet or capsule dosage forms for clients when active pharmaceutical ingredient (API) quantity is limited, and the API potency needs a higher level of protection.
- Oct-2020: Merck & Co., Inc. collaborated with Intec Pharma Ltd., a clinical-stage biopharmaceutical company. This collaboration would be based on the alliance in prior research and enables the companies to leverage their combined experience in delivery.
- Dec-2019: Johnson & Johnson completed the acquisition of TARIS Biomedical LLC, a biotechnology company with expertise in the development of a novel drug delivery technology through TAR-200, the proprietary TARIS System consisting of silicone-based drug delivery device that enables the continuous release of medication into the bladder. Through this acquisition, Johnson & Johnson aims to advance the whole regimen to push towards early interception of bladder cancer to enhance results for patients.
Scope of the Study
Market Segments Covered in the Report:
By Release Mechanism
- Feedback Regulated Drug Delivery Systems
- Activation-modulated Drug Delivery Systems
- Chemically Activated
- Polymer Based Systems
- Micro Reservoir Partition Controlled Drug Delivery Systems
By Technology
- Targeted Delivery
- Coacervation
- Micro Encapsulation
- Transdermal
- Implants
- Wurster Technique
- Others
By Application
- Oral Controlled-drug delivery Systems
- Metered Dose Inhalers
- Injectable
- Transdermal & Ocular Patches
- Infusion Pumps & Drug Eluting Stents
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- Merck & Co., Inc.
- Alkermes PLC
- Pfizer, Inc.
- Assertio Holdings, Inc. (Assertio Therapeutics, Inc.)
- Lonza Group AG (Capsugel)
- Colorcon, Inc. (BPSI Holdings LLC.)
- Corium, LLC (Gurnet Point Capital)
- Adare Pharma Solutions
- Coating Place, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Global Controlled Release Drug Delivery Market by Release Mechanism
Chapter 6. Global Controlled Release Drug Delivery Market by Technology
Chapter 7. Global Controlled Release Drug Delivery Market by Application
Chapter 8. Global Controlled Release Drug Delivery Market by Region
Chapter 9. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Merck & Co., Inc.
- Alkermes PLC
- Pfizer, Inc.
- Assertio Holdings, Inc. (Assertio Therapeutics, Inc.)
- Lonza Group AG (Capsugel)
- Colorcon, Inc. (BPSI Holdings LLC.)
- Corium, LLC (Gurnet Point Capital)
- Adare Pharma Solutions
- Coating Place, Inc.
Methodology
LOADING...
